Vigneswaran Hari T, Discacciati Andrea, Gann Peter H, Grönberg Henrik, Eklund Martin, Abern Michael R
Department of Urology, College of Medicine, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77, Solna, Sweden.
Prostate Cancer Prostatic Dis. 2021 Mar;24(1):120-127. doi: 10.1038/s41391-020-0250-2. Epub 2020 Jul 8.
The Stockholm3 test improves Gleason Grade Group ≥2 (GG ≥ 2) prostate cancer (PC) detection, however it has not been evaluated in an American cohort where clinical practice patterns and ethnicity differ. We aimed to identify subgroups within a Stockholm population with PC risk profiles matching American ethnicity-specific subgroups and compare the detection of PC and describe Stockholm3 performance within these subgroups.
All men age 49-70 years presenting for prostate biopsies were evaluated at UIC from 2016 to 2019, as well as men in Stockholm from 2012 to 2014 in the STHLM3 study. Propensity scores (PS) were estimated for each person using logistic regression for age, PSA, prostate volume, family history of PC, 5-alpha reductase inhibitor use, and prior biopsy. 3:1 PS matching was performed for Stockholm to Chicago ethnicity-specific cohorts and odds ratios (OR) were computed to compare detection of GG ≥ 2 PC between groups.
504 Chicago men and 6980 Stockholm men were included. In African American (AA) men, 51% had GG ≥ 2 PC detected, while in risk-matched Stockholm men, 34% had GG ≥ 2 PC detected (OR: 2.1, p < 0.001). There was no statistical difference in GG ≥ 2 PC detected when matching Stockholm men to non-Hispanic Caucasian men (31% vs. 24%, OR: 0.7, p = 0.30) or Hispanic Caucasian men (31% vs. 27%, OR: 1.2, p = 0.42). The AUC for the Stockholm3 test of the matched Stockholm cohorts for AA, non-Hispanic Caucasian, and Hispanic Caucasian men was 0.85, 0.89, and 0.90, respectively.
Using statistical techniques to simulate a multi-ethnic Chicago cohort within the STHLM3 population, we found an excess risk of GG ≥ 2 PC among AA men. Our hypothesis that the Stockholm3 may have good predictive value in a multiethnic cohort is strengthened, and that recalibration to at least AA men seems likely to be needed to obtain well-calibrated predictions.
Stockholm3检测可提高Gleason分级组≥2(GG≥2)前列腺癌(PC)的检出率,然而尚未在美国队列中进行评估,因为美国的临床实践模式和种族有所不同。我们旨在确定Stockholm人群中PC风险特征与美国特定种族亚组相匹配的亚组,比较PC的检出情况,并描述这些亚组内Stockholm3检测的性能。
2016年至2019年在伊利诺伊大学芝加哥分校对所有年龄在49 - 70岁进行前列腺活检的男性进行评估,同时在2012年至2014年对Stockholm3研究中来自斯德哥尔摩的男性进行评估。使用逻辑回归对年龄、前列腺特异性抗原(PSA)、前列腺体积、PC家族史、5α还原酶抑制剂使用情况和既往活检情况估计每个人的倾向得分(PS)。对斯德哥尔摩与芝加哥特定种族队列进行3:1的PS匹配,并计算优势比(OR)以比较两组之间GG≥2 PC的检出情况。
纳入了504名芝加哥男性和6980名斯德哥尔摩男性。在非裔美国(AA)男性中,51%检测出GG≥2 PC,而在风险匹配的斯德哥尔摩男性中,34%检测出GG≥2 PC(OR:2.1,p < 0.001)。当将斯德哥尔摩男性与非西班牙裔白人男性(31%对24%,OR:0.7,p = 0.30)或西班牙裔白人男性(31%对27%,OR:1.2,p = 0.42)匹配时,GG≥2 PC的检出率无统计学差异。匹配的斯德哥尔摩队列中,AA、非西班牙裔白人和西班牙裔白人男性的Stockholm3检测的曲线下面积(AUC)分别为0.85、0.89和0.90。
通过统计技术在STHLM3人群中模拟多民族芝加哥队列,我们发现AA男性中GG≥2 PC的风险过高。我们关于Stockholm3在多民族队列中可能具有良好预测价值的假设得到了加强,并且似乎需要至少对AA男性进行重新校准以获得校准良好的预测。